XM无法为美国居民提供服务。

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit</title></head><body>

Oct 30 (Reuters) -Diagnostics firm Bio-Rad Laboratories BIO.N posted third-quarter profit above Wall Street estimates on Wednesday,helped by a recovery in demand for analytical tools from its biotech clients and steady clinical diagnostics products sales growth.

Shares of the Hercules, California-based company rose 2.85% to $340 in extended trading.

The company supplies laboratory equipment and instruments for drug manufacturers and biotech companies. Bio-Rad also produces and sells blood and other diagnostic test kits to hospitals and physicians.

Decreased spending in the biotech sector, as well as sluggish demand from China, a key region for drug development, has hit Bio-Rad's profits in recent quarters.

Some analysts are hopeful that a recent interest rate cut by the Federal Reserve could improve funding for small- and medium-sized biotechs and boost demand.

Last week, large rival Thermo Fisher Scientific TMO.N raised its annual profit forecast, banking on demand for its tools and services used in clinical trials.

The company continues to view annual adjusted revenue to decline by about 2.5% to 4%, on a currency-neutral basis.

Sales from the company's clinical diagnostics unit, its largest by revenue, rose 5.6% to $388.8 million.

Bio-Rad posted third-quarter total net sales of $649.7 million, topping analysts' estimates of $628.2 million.

On an adjusted basis, Bio-Rad recorded a per-share profit of $2.01 in the quarter ended Sept. 30, above analysts' estimate of $1.16.



Reporting by Bhanvi Satija and Sruthi Narasimha Chari in Bengaluru; Editing by Alan Barona and Mohammed Safi Shamsi

</body></html>

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明